VCs aren't your buyer; Pharma is

A funding round is a milestone. An acquisition is an outcome. The companies that confuse the two build equity stories that impress investors but leave pharma business development teams cold. The distinction matters more now than at any point in the past decade.

According to McKinsey's analysis of biopharma innovation sourcing, more than 70% of new molecular entity revenues since 2018 have come from externally sourced products. Pharma does not discover most of its own pipeline anymore. It acquires it, licenses it, or co-develops it from the outside. The biotech company that understands this dynamic and builds accordingly is not just more likely to exit. It is more likely to exit at a premium.

Yet most biotech founders design their companies for the capital funnel, not the customer funnel. They optimise for VC metrics: platform breadth, total addressable market, team pedigree, burn rate efficiency. These metrics matter for fundraising. They are largely irrelevant to the pharma BD&L team that will ultimately decide whether to acquire, license, or partner.

This article explains why the disconnect exists, what pharma actually evaluates, and how to build a company that satisfies both audiences by starting with the right one.

The patent cliff is the context for everything

The pharma M&A environment is shaped by a single structural reality: patent cliffs. According to AlphaSense, 190 drug patents are set to expire by 2030, and a drug's price can drop as much as 90% after it loses patent protection. According to EY's Firepower report, Big Pharma faces a growth gap of more than $120 billion by 2028.

The Q1 2026 data confirms the urgency. According to the J.P. Morgan/DealForma Q1 2026 Biopharma Licensing and Venture Report, biopharma M&A totalled $40.9 billion across 32 deals in the first quarter alone, with a median upfront of $1.4 billion. Biopharma licensing reached $82.7 billion in announced value in Q1 2026, following a record $269.6 billion in 2025. Deal structures remained milestone-heavy, with upfront cash representing just 6% of total deal value, highlighting the continued importance of large development, regulatory, and commercial milestone packages.

What pharma actually evaluates

A venture capitalist evaluates your company on risk reduction, team quality, and the probability of a return within the fund's timeline. A pharma BD&L team evaluates something entirely different: strategic fit.

The question is not "is this good science?" The question is: does this asset fill a specific gap in our pipeline, in a therapeutic area where we have commercial infrastructure, at a stage where the remaining risk is manageable, with an IP position that gives us exclusivity long enough to generate a return?

According to the J.P. Morgan/DealForma report, biopharma M&A through Q1 2026 continued to skew toward Phase II, Phase III, and approved-stage companies. The median M&A values for large-cap biopharma acquisitions (2021 to Q1 2026) tell the story precisely.

Five criteria consistently drive pharma acquisition decisions:

1. Mechanism and therapeutic area fit. Does the asset address an indication where the acquirer has existing commercial infrastructure, regulatory expertise, and KOL relationships? A first-in-class mechanism in an area where the acquirer has no presence is worth less than a best-in-class asset in their core franchise.

2. IP architecture. According to Lexology's analysis of the top 2025 biopharma M&A deals, "the best biotech acquisition targets are those with robust legal moats, not just promising Phase II data." Modern acquirers evaluate not just the core patent but the layered IP estate: composition-of-matter, formulation, manufacturing process, method-of-use. Patent depth determines exclusivity horizon, and exclusivity horizon determines deal value.

3. Regulatory pathway clarity. A defined regulatory strategy, ideally with agency interactions on record (pre-IND meetings, scientific advice, orphan drug designation), reduces the acquirer's uncertainty about the path to approval. Regulatory milestones that have been achieved are worth more than milestones that are planned.

4. Commercial model viability. Can this asset be priced, reimbursed, and distributed within the acquirer's existing cost structure? A therapy that requires a new distribution model or a specialised sales force is a different proposition from one that slots into existing infrastructure.

5. Competitive positioning. Where does this asset sit relative to other compounds in development for the same indication? Pharma BD&L teams map the competitive landscape with precision. An asset that is sixth-to-market in a crowded indication, even with strong data, is less attractive than a differentiated asset in a less populated space.

The capital funnel and the customer funnel are not the same

The capital funnel (angels, seed, Series A, Series B) operates on different logic from the customer funnel (preclinical, IND, Phase I, BD discussions). VCs evaluate risk reduction and team quality within the context of their fund's return model. Pharma evaluates strategic value within the context of its portfolio gaps and competitive dynamics.

The best companies design milestones that satisfy both. But they start with the exit in mind.

This means building for pharma requirements from the beginning: robust IP around a clear mechanism, regulatory strategies that de-risk the approval pathway, and a development plan that generates the data pharma needs to make a purchase decision, not just the data VCs need to make a funding decision.

It also means avoiding misaligned capital. Investors who push for platform breadth when pharma wants asset specificity. Investors who expect software-style growth curves from biology. Investors who optimise for IPO metrics when the realistic exit is a trade sale. The capital source shapes the company's trajectory, and a trajectory designed for the wrong buyer leads to a company that is fundable but not acquirable.

What "building backwards from pharma" looks like in practice

The pharma purchase decision has a specific architecture. Building backwards from it means starting with five questions that most founders address last, if at all.

Who is the buyer? Not "who might be interested" but "which specific companies have a gap in this therapeutic area, at this stage, with this commercial infrastructure?" This is not a theoretical exercise. It requires mapping the acquirer's pipeline, their patent cliff exposure, their recent BD activity, and their publicly stated strategic priorities.

What triggers the purchase? Pharma BD&L teams do not acquire on impulse. They acquire when a specific trigger creates urgency: a patent cliff approaching, a competitor's clinical readout that changes the landscape, a regulatory designation that validates the pathway, or a Phase II result that shifts the probability of success above the acquirer's internal threshold.

At what stage and at what price? The stage at which pharma acquires determines the valuation. Median M&A upfront values for large-cap pharma range from $150 million at platform/discovery to $7.25 billion at approval. Understanding where your asset sits on this curve determines how much capital you need to raise and how far you need to advance before the exit.

What data does the buyer need? This is the critical alignment point. The data that impresses a VC (TAM slides, team bios, market projections) is not the data that drives a pharma acquisition. Pharma needs clinical data in the right patient population, in the right endpoint, with the right comparator. Regulatory interactions on record. Freedom-to-operate opinions. Manufacturing feasibility at scale.

What IP position makes the asset defensible? The acquirer is not buying your compound. They are buying years of exclusivity. The IP estate must be designed from day one to create layered protection that delays generic or biosimilar entry. This is not a legal afterthought. It is a core element of the company's value proposition.

Why this matters more in 2026

The environment has shifted decisively. According to the J.P. Morgan/DealForma Q1 2026 report, biopharma venture funding came in at $6.9 billion across 101 deals in Q1 2026, down from $8.6 billion in Q1 2025. Seed and Series A funding totalled $2.3 billion across just 50 deals, well below Series B+ activity at $4.5 billion across 51 deals. First-time financings are on pace for their lowest annual count since before COVID. Capital deployment remains focused on established portfolio companies with advanced pipelines and upcoming clinical catalysts.

The message from the data is clear: investors are rewarding later-stage conviction over broad early-stage exploration. The median venture round for a Phase III company in Q1 2026 reached $108 million, compared to $39 million for preclinical. Meanwhile, licensing activity remains robust, with 15 R&D licensing deals disclosing upfront payments above $100 million in Q1 2026 alone. Large-cap biopharma continues to use licensing and M&A to secure differentiated assets, while the venture market narrows.

For biotech founders, this means the pharma exit is not an alternative to the VC path. It is increasingly the path. The companies that close the best exits are the ones that understood, from day one, that the VC is the vehicle and pharma is the destination.

Frequently asked questions